Day 3 of ASRI #ASRI2022 is starting... Join us for Business Meeting and delicious breakfast. (Dr. Chuck Wira promised to open his Twitter account.)

So happy and excited to see your previous colleague showing a wonderful talk at our ASRI .She overcame a lot of difficulties to get here from oversea. #ASRI2022

#ASRI2022 Great talk on Heterogeneity of decidual CD8 T cells presented by Tamara Tilburgs

Studying at conference ASRI and Dr. Enninga Elizabeth Enninga, PhD just presented her wonderful work on T cells in placental villitis. #ASRI2022

Congrats to my great mentor Dr. Burd Irina Burd, MD, PhD won the ASRI ASRI distinguished service award! Many thanks to Dr. Burd’s efforts for making this conference so fantastic!! #ASRI2022

GREAT #ASRI2022 in Nashville this year. See you in Santa Fe in 2023!!! Join ASRI TODAY!!!

Great thanks to my mentor Dr. Burd’ guidance Irina Burd, MD, PhD and my lovely colleagues Jun Lei, MD, PhD Yang Liu , who always give me the support and help. Thanks ASRI ASRI for giving me this opportunity to present my work. #ASRI2022

Annual ASRI Awards Gala is a blast! #ASRI2022 Dr. Indira Mysorekar @DMAronoff 💃 🕺🏼

It's a wrap: #ASRI2022!! FANTASTIC meeting and great fun organizing with my fav folks Irina Burd, MD, PhD @DMAronoff . 🙏🏽. Outstanding science and tons of fun. Next up: ASRI2023 in Santa Fe! Irina Burd, MD, PhD Gil Mor and Drs. Wira and Sharma

2023: The rise of precision cellular therapies. In this Year in Review, I highlight 3 major advances set to transform the treatment of autoimmune and rheumatic diseases. From CAR-T cells to antigen-specific, precision immunotherapies. Link: rdcu.be/dvsaG

INBT associate researcher Max Konig has been working to develop precision therapies by building on advances in gene engineering that could allow patients to escape the life-threatening complications with current therapies for autoimmune disease. inbt.jhu.edu/precision-ther…

Congrats to Steph Glavaris for being awarded the ACR Emerging Investigator Excellence Award for her work on T cell-engaging antibodies to deeply deplete TRBV9+, autoreactive T cells in ankylosing spondylitis and celiac disease. #ACR24 Johns Hopkins Rheumatology Chris Marston #ProundMentorMoment

While at it, if you are interested in learning more about off-the-shelf precision immunotherapies for the treatment of lupus, please join our talk on 9G4xCD3 T cell-engaging antibodies during the SLE - Cellular Therapy Session at 3 PM. #ACR24 Johns Hopkins Medicine Johns Hopkins Rheumatology

Targeting autoreactive B-cells in lupus is a successful treatment, but can cause immunosuppression. Jin Liu’s study details a new T-cell therapy that can selectively eliminate certain B cells in patients with lupus, while avoiding complete immunosuppression. #ACR24

Grateful for the incredible experience at #ACR2024! Honored to present my work! A huge thank you to my mentor, Max Konig for all your guidance and support, and to organizer American College of Rheumatology for this amazing opportunity and recognition! Shout out to our collaborators@jhrheumatology

Heartfelt thank you to my mentor Max Konig for invaluable guidance and support! And shout out to my incredible teammates for collaboration and encouragement! None of this would be possible without you all!

In a session on new therapies for autoimmune diseases, Max Konig discusses his research with CAR-T cell treatment, showing how specific immune cells can be targeted to treat conditions such as lupus without compromising the immune system. #ACR24

Precision targeting of autoreactive B cells in systemic lupus erythematosus using anti-9G4 idiotope synthetic immune receptor T cells biorxiv.org/content/10.110… #biorxiv_immuno

We are excited to shared our latest work on bioRxiv: “Precision targeting of autoreactive 9G4 idiotope B cells in systemic lupus erythematosus (SLE) using engineered CAR- and cTCR-T cells”. Here’s a snapshot of what we did + why it matters: The problem: Current B-cell depleting